Review Article: The Rationale for a Multimodal Approach in the Management of Breakthrough Cancer Pain: A Review

Abstract

Breakthrough pain has been described differently in various countries, and not surprisingly, recommendations for its management vary according to the institution. Usually when breakthrough pain occurs, the patient's pain has already been managed according to the World Health Organization 3-step ladder for cancer pain. After this point, the treatment choice is usually based on clinical judgment, the physician's personal experience with interventional procedures, and local resources available. Opioids remain the mainstay of the management of breakthrough cancer pain. However, the combination of radio-oncology, adjuvant drugs, and interventional pain procedures can improve pain relief. This review addresses those questions and proposes a multimodal approach to manage breakthrough cancer pain.

Keywords

cancer pain breakthrough pain cancer pain management

Get full access to this article

View all access options for this article.

References

Levy MH Pharmacologic treatment of cancer pain. N Engl J Med. 1996;335:1124-1132.

Sykes J. , Johnson R. , Hanks GW ABC of palliative care: difficult pain problems. BMJ. 1997;315:867-869.

Portenoy RK , Hagen N. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.

Portenoy RK , Payne D. , Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain . Pain. 1999;21:129-134.

Bruera E. , Scholler T. , Wenk R. , et al. A prospective multi-center assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995;10:348-355.

Mercadante S. , Maddaloni S. , Roccella S. , Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain. 1992;50:151-155.

Hwang SS , Chang V. , Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55-64.

Caraceni A. , Martini C. , Zecca E. , et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-183.

Fine PG , Busch M. Characterization of breakthrough pain by hospice patients and their caregivers . J Pain Symptom Manage. 1998;16:179-183.

10.

Zeppetella G. , O'Doherty CA Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.

11.

Stromgren A. , Groenvold M. , Petersen MA , et al. Pain characteristics and treatment outcome for advanced cancer patients during the first week of specialized palliative care. J Pain Symptom Manage. 2004 ;27:104-113.

12.

Banning A. , Sjogren P. , Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain. 1991;47: 129-134.

13.

Svendsen K. , Andersen A. , Sigurdur A. , et al. Breakthrough pain in malignant and nonmalignant diseases: a review of prevalence, characteristics and mechanisms . Eur J Pain. 2005;9:195-206.

14.

Caraceni A. , Weinstein SM Classification of cancer pain syndromes . Oncology. 2001;15:1627-1642.

15.

Mercadante S.

What is the definition of breakthrough pain?

Pain. 1991;45:107-108.

16.

Sze WM , Shelley MD , Held I. , Wilt TJ , Mason MD Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy—a systematic review of randomised trials. Clin Oncol (R Coll Radiol). 2003;15: 345-352.

17.

Bauman G. , Charette M. , Reid M. , Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis—a systemic review. Radiother Oncol. 2005;75: 258-270.

18.

Ripamonti C. , Fagnoni E. , Campa T. , Seregni E. , Maccauro M. , Bombardieri E. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study . Support Care Cancer . 2007;15:339-422.

19.

Mercadante S. , Casuccio A. , Agnello A. , et al. Analgesic effects of nonsteroidal anti-inflamatory drugs in cancer pain due to somatic or visceral mechanism . J Pain Symptom Manage. 1999;17:351-356.

20.

World Health Organization Expert Committee. Cancer Pain Relief and Palliative Care. Geneva, Switzerland, World Health Organization; 1992 .

21.

Mercadante S. , Radbruch L, Caraceni , et al. Episodic (breakthrough) pain. Consensus conference of an expert working group of the European Association for Palliat Care. Cancer. 2002;94:832-889.

22.

Davis M. , Walsh D. , Lagman R. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6:696-704.

23.

Tannock I. , Gospodarowicz M. , Meakin W. , Panzarella T. , Stewart L. , Rider W. Treatment of metastatic prostatic cancer with low dose prednisone: evaluation of pain and quality of life as pragmatic indices of responses. J Clin Oncol 1989;7:590-597.

24.

Vrionis FD , Miguel R.

Management of spinal metastases. Semin

Pain Med. 2003;1:25-33.

25.

Fainsinger RL , Spachynski K. , Hanson J. , et al. Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage. 1994;9:12-18.

26.

Mercadante S. Malignant bone pain: pathophysiology and treatment . Pain. 1997;69:1-18.

27.

Mercadante S. , Villari P. , Ferrera P. , Dabbene M. Pamidronate in incident pain due to bone metastases . J Pain Symptom Manage . 2001;22:630-631.

28.

Rosen LS , Gordon D. , Kaminski M. , et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;5:377-387.

29.

Hirsh V. , Tchekmedyian NS , Rosen LS , et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004;3:170-174.

30.

Heidenreich A. , Ohlmann C. , Body JJ Ibandronate in metastatic bone pain. Semin Oncol. 2004;31:67-72.

31.

Ripamonti C. , Mercadante S. , Groff L. , Zecca E. , De Conno F. , Casuccio A. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19:23-34.

32.

Mercadante S. , Ripamonti C. , Casuccio A. , et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000 ;8:188-191.

33.

Petzke F. Radbruch L. , Zech D. , Loick G. , Grond S. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage. 1999;17:391-401.

34.

Dworkin RH , Backonja M. , Rowbotham MC , et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.

35.

Sindrup SH , Bach FW , Madsen SW , et al. Venlafaxine versus imipramine in painful neuropathy: a randomized controlled trial. Neurology. 2003;60:1284-1289.

36.

Caraceni A. , Zecca E. , Martini C. , et al. Gabapentin as an adjuvant to opioid analgesia in cancer pain. J Pain Symptom Manage. 1999;17:441-445.

37.

Caraceni A. , Zecca E. , Bonezzi C. , et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004 ;22:2909-2917.

38.

Turan A. , White P. , Karamanlioglu B. Gabapentin: an alternative to the cyclooxygenase-2 inhibitors for perioperative pain management. Anesth Analg. 2006;102:175-181.

39.

Lukats-Tremont IW , Challapalli V. , McNicol ED Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101:1738-1749.

40.

Bruera E. , Ripamonti C. , Brenneis C. A randomized double blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage . 1992;7:138-140.

41.

Mercadante S. , Lodi F. , Sapio M. , Calligara M. , Serretta R. Long-term ketamine subcutaneous continous infusion in neuropathic cancer pain. J Pain Symptom Manage . 1995;10:564-567.

42.

Fine PG Low dose ketamine in the management of opioid non-responsive teminal cancer pain. J Pain Symptom Manage. 1999;17:296-300.

43.

Mercadante S. , Arcuri E. , Tirelli W. , Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double blind, crossover, double dose study. J Pain Symptom Manage. 2000;4:246-251.

44.

Carr DB , Goudas CL , Denman W. , et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108:17-27.

45.

Roth SH Efficacy and safety of tramadol HCL in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998;25:1358-1363.

46.

Mercadante S. , Villari P. , Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage. 2004;28:505-510.

47.

Collins SL , Faura CC , Moore RA , McQuay HJ Peak plasma concentrations after oral morphine: a systematic review . J Pain Symptom Manage. 1998;16:388-402.

48.

Fisher K. , Stiles C. , Hagen N. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. 2004;28:618-625.

49.

Cherny NJ , Chang V. , Frager G. , et al. Opioid pharmacotherapy in the management of cancer pain. Cancer. 1995;76:1283-1293.

50.

Elsner F. , Radbruch L. , Loick G. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliat Med. 2005;8: 743-750.

51.

Mercadante S. , Villari P. , Ferrera P. , et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage. 2004;27: 352-359.

52.

Mercadante S. , Villari P. , Ferrera P. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine . J Pain Symptom Manage. 2006;32:172-179.

53.

Kunz KM , Theisen JA , Schroeder ME Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage. 1993;8:189-190.

54.

Payne R. , Coluzzi P. , Hart L. , et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Manage. 2001;22:575-583.

55.

Aronoff G. , Brennan M. , Pritchard D. Evidence-based oral transmucosal fentanyl citrate dosing guidelines . Pain Med. 2005;4:305-314.

56.

Zeppettela G. , Ribeiro MD Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006 25;1:CD004311.

57.

Portenoy RK , Payne R. , Coluzzi P. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain . 1999;79:303-312.

58.

Colleau S. The significance of breakthrough pain. WHO. Cancer Pain Release . 1999;124:1-8.

59.

Portenoy RK , Taylor D. , Messina J. , Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.

60.

Darwish M. , Robertson P. Jr , Tracewell W. , et al. Comparative bioavailability of the novel fentanyl effervescent buccal tablet formulation: an open-label crossover study. J Pain. 2006;7(4 suppl 1):35.

61.

Portenoy R. Managing pain in patients with advanced cancer: the role of neuroaxial infusion. Oncology (Williston Park). 1999;13(5suppl2):7-8.

62.

Van Dogen RT , Crul BJ , DeBock M. Long term intrathecal infusion of morphine and morphine/bupivacaine in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain. 1993;55:119-123.

63.

Eisenach JC , DuPen S. , Dubois M. , Miguel R. , Allin D. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995;61:391-399.

64.

Rauck RL , Cherry D. , Boyer MF

Long-term intrathecal opioid therapy with a patient-activated implanted delivery system for the treatment of refractory cancer pain. J

Pain . 2003;4:441-447.

65.

Mercadante S. , Arcuri E. , Ferrera P. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain . J Pain Symptom Manage. 2005;30:485-491.

66.

Mercadante S. Problems with long-term spinal opioid treatment in advanced cancer patients. Pain. 1999;79: 1-13.

67.

Lieberman I. , Reinhardt MK Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop Relat Res. 2003;41(5 suppl):S176-S186.

68.

Burton AW , Reddy S. , Shah H. Percutaneous vertebroplasty—a technique to treat refractory spinal pain in the setting of advanced metastatic cancer: a case series. J Pain Symptom Manage. 2005;30:87-95.

69.

Jang JS , Lee SH

Efficacy of percutaneous vertebroplasty combined with radiotherapy in osteolytic metastatic spinal tumors. J Neurosurg

Spine. 2005;3:243-248.

70.

Mameli S. , Frau L. , Orru A. , Marchi A. , Corbucci GG Percutaneous cervical cordotomy in the therapy of incident pain. Minerva Anestesiol. 2002;68:919-929.

71.

Sanders M. , Zuurmond W. Safety of unilateral and bilateral percutaneous cervical cordotomy in 80 terminally ill cancer patients. J Clin Oncol. 1995;13: 1509-1512.

72.

Jones B. , Finlay I. , Ray A.

Is there still a role for open cordotomy in cancer pain management?

J Pain Symptom Manage. 2003;25:179-184.